Literature DB >> 2544891

Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells.

U C Wargalla1, R A Reisfeld.   

Abstract

The relationship between the cellular internalization of an anti-ganglioside GD2 monoclonal antibody (14.G2a) and the toxic effect of its ricin A-chain immunotoxin (14.G2a-RA) was examined on GD2-bearing M21 human melanoma and T293 small cell lung carcinoma cell lines. The capacity for ligand uptake was determined by examining the parameters that contribute to this constant, including the number of cell-surface binding sites and the internalization rate constant (ke). The maximum uptake of 14.G2a is 11-fold greater for M21 than for T293 cells, due to a 2.7-fold difference in binding sites and a 4-fold difference in the rate of antibody internalization. The capacity for ligand uptake correlates with the cytotoxic activity of the 14.G2a-RA immunotoxin against these two cell lines. Furthermore, we were able to demonstrate that the consequence of internalization of 14.G2a-RA is the intracellular release of undegraded ricin A-chain from the antibody. These studies indicate that the rate of internalization is a quantitative parameter that plays a key role in predicting the cytotoxic potency of this immunotoxin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544891      PMCID: PMC297574          DOI: 10.1073/pnas.86.13.5146

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.

Authors:  O W Press; P J Martin; P E Thorpe; E S Vitetta
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution.

Authors:  R J Youle; D M Neville
Journal:  J Biol Chem       Date:  1982-02-25       Impact factor: 5.157

4.  Immunotoxins: a new approach to cancer therapy.

Authors:  E S Vitetta; K A Krolick; M Miyama-Inaba; W Cushley; J W Uhr
Journal:  Science       Date:  1983-02-11       Impact factor: 47.728

5.  The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis.

Authors:  H S Wiley; D D Cunningham
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

6.  A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells.

Authors:  V Raso; M Basala
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

7.  Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.

Authors:  P Casellas; B J Bourrie; P Gros; F K Jansen
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

8.  Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells.

Authors:  H T Haigler; F R Maxfield; M C Willingham; I Pastan
Journal:  J Biol Chem       Date:  1980-02-25       Impact factor: 5.157

9.  Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins.

Authors:  J M Lambert; P D Senter; A Yau-Young; W A Blättler; V S Goldmacher
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

10.  Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells.

Authors:  T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

View more
  26 in total

1.  Target-mediated drug disposition model for drugs that bind to more than one target.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-29       Impact factor: 2.745

2.  Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.

Authors:  Zhengyuan Zhou; Ganesan Vaidyanathan; Darryl McDougald; Choong Mo Kang; Irina Balyasnikova; Nick Devoogdt; Angeline N Ta; Brian R McNaughton; Michael R Zalutsky
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

3.  A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.

Authors:  K Mujoo; R A Reisfeld; L Cheung; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Different cytotoxic activity and intracellular fate of an anti-CD5-momordin immunotoxin in normal compared to tumour cells.

Authors:  G Porro; P Lento; F Marcucci; G Gromo; D Modena
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 5.  Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.

Authors:  D M Ashley; S K Batra; D D Bigner
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

6.  Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.

Authors:  Jacob L Houghton; Brian M Zeglis; Dalya Abdel-Atti; Ritsuko Sawada; Wolfgang W Scholz; Jason S Lewis
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

Review 7.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

8.  Internalization of an intact doxorubicin immunoconjugate.

Authors:  L B Shih; D M Goldenberg; H Xuan; H W Lu; M J Mattes; T C Hall
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

9.  A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.

Authors:  P Casalini; M Caldera; S Canevari; S Ménard; D Mezzanzanica; E Tosi; M Gadina; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

10.  Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Authors:  Antoni Ribas; John M Kirkwood; Michael B Atkins; Theresa L Whiteside; William Gooding; Andreas Kovar; Stephen D Gillies; Oscar Kashala; Michael A Morse
Journal:  J Transl Med       Date:  2009-07-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.